A Novel 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine

Journal of Analytical Toxicology

Volumn 40, Issue 1, 2016, Pages 17-27

  Lawson, Alexander J ^a   Shipman, Kate E ^a   George, Stephen ^a   Dasgupta, Indranil ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BISOPROLOL; CANDESARTAN; DILTIAZEM; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; MOXONIDINE; NIFEDIPINE; PERINDOPRIL; RAMIPRIL; SPIRONOLACTONE; VERAPAMIL;

ACCURACY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STABILITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEDICATION COMPLIANCE; REPRODUCIBILITY; RESISTANT HYPERTENSION; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; ANALYSIS; CORONARY VASOSPASM; EVALUATION STUDY; HYPERTENSION; PATIENT COMPLIANCE; PROCEDURES; URINE;

ANALYTIC SAMPLE PREPARATION METHODS; ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY VASOSPASM; HUMANS; HYPERTENSION; LIMIT OF DETECTION; PATIENT COMPLIANCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84960093898     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkv102     Document Type: Article

References (28)

1. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217-223.
2. WHO. (2010) Global Status Report on Non-communicable Diseases. WHO Press, World Health Organization: Geneva, Switzerland.
3. Musini, V.M., Tejani, A.M., Bassett, K., Wright, J.M. (2009) Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews, 7, CD000028.
4. Pickering, T.G., Shimbo, D., Haas, D. (2006) Ambulatory blood-pressure monitoring. The New England Journal of Medicine, 354, 2368-2374.
5. Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D. et al. (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 117, e510-e526.
6. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M. et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 31, 1281-1357.
7. NICE. (2011) National Institute for Health and Clinical Excellence Clinical Guideline 127. Hypertension: Clinical Management of Primary Hypertension in Adults. https://www.nice.org.uk/guidance/CG127 (accessed Aug 24, 2015).
8. Daugherty, S.L., Powers, J.D., Magid, D.J., Tavel, H.M., Masoudi, F.A., Margolis, K.L. et al. (2012) Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation, 125, 1635-1642.
9. DiMatteo, M.R. (2004) Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care, 42, 200-209.
10. Mazzaglia, G., Mantovani, L.G., Sturkenboom, M.C., Filippi, A., Trifiro, G., Cricelli, C. et al. (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of Hypertension, 23, 2093-2100.
11. VanWijk, B.L., Klungel, O.H., Heerdink, E.R., de Boer, A. (2005) Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension, 23, 2101-2107.
12. Elliott, W.J. (2009) Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. The Journal of Clinical Hypertension, 11, 376-382.
13. Romanelli, R.J., Schiro, T.A., Jukes, T., Wong, K.S., Ishisaka, D.Y. (2011) Disparities in blood pressure control within a community-based provider network: anexploratoryanalysis.Annals ofPharmacotherapy, 45, 1473-1482.
14. Jung, O., Gechter, J.L., Wunder, C., Paulke, A., Bartel, C., Geiger, H. et al. (2013) Resistant hypertension? Assessment of adherence by toxicological urine analysis. Journal of Hypertension, 31, 766-774.
15. Appunu, K., Tesbitt, L., Jacques, N., Hadley, G., Thomas, M., Dasgupta, I. (2012) Confirmation of drug adherence before renal sympathetic denervation-the role of drug efficacy clinic. Journal of Human Hypertension, 26, 635-636.
16. WHO. (2003) Adherence to Long-Term Therapies: Evidence for Action. WHO Press, World Health Organization: Geneva, Switzerland.
17. Bunker, J., Callister, W., Chang, C.L., Sever, P.S. (2011) How common is true resistant hypertension? Journal of Human Hypertension, 25, 137-140.
18. Meyer, M.R., Weber, A.A., Maurer, H.H. (2011) A validated GC-MS procedure for fast, simple, and cost-effective quantification of glycols and GHB in human plasma and their identification in urine and plasma developed for emergency toxicology. Analytical and Bioanalytical Chemistry, 400, 411-414.
19. Waldron, J., Webster, C. (2011) Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins. Annals of Clinical Biochemistry, 48, 223-232.
20. Marrington, R., Johnston, J., Knowles, S., Webster, C. (2010) Measurement of urinary metadrenaline and normetadrenaline by liquid chromatography tandem mass spectrometry for the diagnosis of phaeochromocytoma. Annals of Clinical Biochemistry, 47, 467-475.
21. Owen, L.J., Adaway, J.E., Davies, S., Neale, S., El-Farhan, N., Ducroq, D. et al. (2013) Development of a rapid assay for the analysis of serum cortisol and its implementation into a routine service laboratory. Annals of Clinical Biochemistry, 50, 345-352.
22. Eichhorst, J.C., Etter, M.L., Hall, P.L., Lehotay, D.C. (2012) LC-MS/MS techniques for high-volume screening of drugs of abuse and target drug quantitation in urine/blood matrices. Methods in Molecular Biology, 902, 29-41.
23. Guddat, S., Solymos, E., Orlovius, A., Thomas, A., Sigmund, G., Geyer, H. et al. (2011) High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Testing and Analysis, 3, 836-850.
24. Costa, F.V. (1996) Compliance with antihypertensive treatment. Clinical and Experimental Hypertension, 18, 463-472.
25. Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P., Yao, X. (2008) Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, 16, CD000011.
26. Bramlage, P., Ketelhut, R., Fronk, E.M., Wolf, W.P., Smolnik, R., Zemmrich, C. et al. (2014) Clinical impact of patient adherence to a fixeddose combination of olmesartan, amlodipine and hydrochlorothiazide. Clinical Drug Investigation, 34, 403-411.
27. Eckert, H.G., Badian, M.J., Gantz, D., Kellner, H.M., Volz, M. (1984) Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittelforschung, 34, 1435-1447.
28. Tomaszewski, M., White, C., Patel, P., Masca, N., Damani, R., Hepworth, J. et al. (2014) High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart, 100, 855-861.